Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Nivolumab 5Magnetic Resonance Spectroscopy 5Specimen Handling 4pembrolizumab 2Ipilimumab 2Immunoglobulin G 2tislelizumab 1temsirolimus 1spartalizumab 1sargramostim 1regorafenib 1pemigatinib 1eribulin 1cabozantinib 1brivanib 1avelumab 1X-Rays 1Valproic Acid 1Sirolimus 1Radiosurgery 1Mifepristone 1Fluorodeoxyglucose F18 1FAPI-46 1Docetaxel 1Disulfides 1Cyclophosphamide 1Cryosurgery 1Colony-Stimulating Factors 1Clinical Trials, Phase II as Topic 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Mifepristone × Sarcoma × Clear all
NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡